Evidence map›Paper›PMID 39338278›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

Botany, Traditional Use, Phytochemistry, Pharmacology and Quality Control of

Jianhao Wu, Jialin Sun, Meiqi Liu, Xiaozhuang Zhang, Lingyang Kong, Lengleng Ma, Shan Jiang, Xiubo Liu, Wei Ma

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Bioactive Compounds from Dandelion (Foods (Basel, Switzerland) · 2026
    Review
  5. Review
  6. Article
  7. Antidiabetic Potential ofPlants (Basel, Switzerland) · 2025
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jianhao WuSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.ORCID 0009-0003-2786-2276
Jialin SunSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.ORCID 0000-0002-3642-8055
Meiqi LiuSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.
Xiaozhuang ZhangSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.
Lingyang KongSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.
Lengleng MaSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.
Shan JiangSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.
Xiubo LiuSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.
Wei MaSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China.

Funding

Heilongjiang Touyan Innovation Team Program [2019] No. 5National Key Research and Development Project, research and demonstration of collection,screening, and breeding technology of ginseng and other genuine medicinal materials 2021YFD1600901Study on Growth and Quality Optimization of Artificial Cultivation of Bupleurum chinense LBH-Z23276
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

botanypharmacologyphytochemistryquality controlreviewTaraxaci herba

Identifiers

PMID39338278
PMCPMC11434673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.